Investing.com UK on Nostr: AstraZeneca disappointed with failure of immunotherapy in early-stage lung cancer ...
AstraZeneca disappointed with failure of immunotherapy in early-stage lung cancer
==========
AstraZeneca's Imfinzi immunotherapy failed to achieve statistical significance in a Phase III trial for early-stage non-small cell lung cancer. The trial tested the drug's efficacy in disease-free survival compared to a placebo after complete tumor resection in patients with tumors expressing the 'PD-L1' checkpoint protein on 25% or more tumor cells. AstraZeneca expressed disappointment in the results but noted that Imfinzi has been successful in other Phase III trials for patients with earlier stages of lung cancer.
#Astrazeneca #Imfinzi #Immunotherapy #LungCancer #PhaseIiiTrial
https://uk.investing.com/news/stock-market-news/astrazeneca-disappointed-with-failure-of-immunotherapy-in-earlystage-lung-cancer-3561449
==========
AstraZeneca's Imfinzi immunotherapy failed to achieve statistical significance in a Phase III trial for early-stage non-small cell lung cancer. The trial tested the drug's efficacy in disease-free survival compared to a placebo after complete tumor resection in patients with tumors expressing the 'PD-L1' checkpoint protein on 25% or more tumor cells. AstraZeneca expressed disappointment in the results but noted that Imfinzi has been successful in other Phase III trials for patients with earlier stages of lung cancer.
#Astrazeneca #Imfinzi #Immunotherapy #LungCancer #PhaseIiiTrial
https://uk.investing.com/news/stock-market-news/astrazeneca-disappointed-with-failure-of-immunotherapy-in-earlystage-lung-cancer-3561449